Clearline Capital LP Reduces Holdings in Nautilus Biotechnology, Inc. (NASDAQ:NAUT)

Clearline Capital LP trimmed its stake in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) by 12.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 144,187 shares of the company’s stock after selling 19,886 shares during the quarter. Clearline Capital LP owned approximately 0.11% of Nautilus Biotechnology worth $411,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the stock. Price T Rowe Associates Inc. MD increased its stake in shares of Nautilus Biotechnology by 35.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 16,078 shares of the company’s stock worth $48,000 after buying an additional 4,239 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Nautilus Biotechnology during the third quarter worth about $50,000. The Manufacturers Life Insurance Company bought a new stake in shares of Nautilus Biotechnology in the third quarter worth about $67,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Nautilus Biotechnology by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 24,121 shares of the company’s stock worth $69,000 after purchasing an additional 9,404 shares during the last quarter. Finally, MetLife Investment Management LLC purchased a new position in Nautilus Biotechnology during the 3rd quarter valued at about $87,000. 50.71% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, VP Mary E. Godwin sold 35,000 shares of the stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $2.85, for a total value of $99,750.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 40.50% of the company’s stock.

Nautilus Biotechnology Stock Performance

NASDAQ NAUT opened at $2.24 on Monday. The stock has a market cap of $281.26 million, a P/E ratio of -4.00 and a beta of 1.23. Nautilus Biotechnology, Inc. has a fifty-two week low of $2.19 and a fifty-two week high of $3.45. The stock has a 50 day simple moving average of $2.64 and a two-hundred day simple moving average of $2.59.

Nautilus Biotechnology (NASDAQ:NAUT) last announced its quarterly earnings results on Tuesday, October 29th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.04. During the same period in the previous year, the business posted ($0.13) earnings per share. Sell-side analysts predict that Nautilus Biotechnology, Inc. will post -0.57 earnings per share for the current year.

Nautilus Biotechnology Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.